Literature DB >> 21270228

Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents.

Stefan Riedel1, Stephen W Eisinger, Lisa Dam, Paul D Stamper, Karen C Carroll.   

Abstract

Recovery of Candida spp. using the BD Bactec FX blood culture (BC) system (Bactec Plus Aerobic/F medium) and the VersaTREK system (aerobic Redox medium) was evaluated using seeded BC bottles with and without the addition of commonly used antifungal agents. BC bottles (n = 1,442) were each inoculated with 10 ml human whole blood and 0.1 ml of suspensions of Candida spp., with or without antifungal agents. BC bottles were incubated in the corresponding system for a maximum of 5 days. In the absence of antifungal agents, Bactec FX recovered 97.4% of Candida spp., and VersaTREK recovered 99.1% (P = 0.154). With regard to length of time to detection (LTD) and overall recovery, both systems had various levels of effectiveness in recovering C. glabrata. In bottles containing antifungal agents, Bactec FX recovered 83.1% of isolates, whereas VersaTREK recovered 50.7% of Candida spp. (P < 0.001). For BC bottles without the addition of antifungal agents, the median LTD for VersaTREK was 2.2 h faster than that of Bactec FX (P < 0.001). In the presence of antifungal agents, the Bactec FX recovery time was significantly faster than that of VersaTREK (median difference of 10.8 h, P < 0.001). We conclude that both systems have comparable abilities to recover Candida spp. from seeded blood cultures in the absence of antifungal agents. In the presence of therapeutic levels of commonly used antifungal agents, the Bactec FX system demonstrated a significantly greater recovery of various Candida spp., as well as a shorter LTD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270228      PMCID: PMC3122833          DOI: 10.1128/JCM.02260-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.

Authors:  M A Pfaller; A Espinel-Ingroff; R N Jones
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media.

Authors:  Benjamin J George; Lynn L Horvath; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

Authors:  Theoklis E Zaoutis; Jesse Argon; Jaclyn Chu; Jesse A Berlin; Thomas J Walsh; Chris Feudtner
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

4.  Times to detection of bacteria and yeasts in BACTEC 9240 blood culture bottles.

Authors:  B S Reisner; G L Woods
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

5.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

Authors:  A S Kao; M E Brandt; W R Pruitt; L A Conn; B A Perkins; D S Stephens; W S Baughman; A L Reingold; G A Rothrock; M A Pfaller; R W Pinner; R A Hajjeh
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

6.  National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.

Authors:  M S Rangel-Frausto; T Wiblin; H M Blumberg; L Saiman; J Patterson; M Rinaldi; M Pfaller; J E Edwards; W Jarvis; J Dawson; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

7.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection.

Authors:  Lynn L Horvath; Benjamin J George; Clinton K Murray; Linda S Harrison; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

9.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  Detection of simulated candidemia by the BACTEC 9240 system with plus aerobic/F and anaerobic/F blood culture bottles.

Authors:  Lynn L Horvath; Duane R Hospenthal; Clinton K Murray; David P Dooley
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

View more
  10 in total

1.  The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?

Authors:  Michael Osthoff; Nina Khanna; Martin Siegemund
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Comparison of the Bactec Fx Plus, Mycosis IC/F, Mycosis/F Lytic blood culture media and the BacT/Alert 3D FA media for detection of Candida species in seeded blood culture specimens containing therapeutic peak levels of fluconazole.

Authors:  Dong Wook Jekarl; So-Young Lee; Seungok Lee; Yeon-Joon Park; Jehoon Lee; Sun Mi Baek; Yeon Ju An; Sun Myeong Ock; Mi-Kyung Lee
Journal:  J Clin Lab Anal       Date:  2012-11       Impact factor: 2.352

Review 3.  Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit.

Authors:  Patrick R Murray; Henry Masur
Journal:  Crit Care Med       Date:  2012-12       Impact factor: 7.598

4.  Impact of systemic antifungal therapy on the detection of Candida species in blood cultures in clinical cases of candidemia.

Authors:  S Bailly; C Garnaud; M Cornet; P Pavese; R Hamidfar-Roy; L Foroni; S Boisset; J-F Timsit; D Maubon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-02       Impact factor: 3.267

5.  Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.

Authors:  Yan Wang; Jiao Xie; Yuanming Xing; Lu Chen; Ying Li; Ti Meng; Weihua Dong; Xue Wang; Yalin Dong
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

6.  In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals.

Authors:  Nicholas D Beyda; Jonathan Amadio; Jose R Rodriguez; Karen Malinowski; Kevin W Garey; Audrey Wanger; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

7.  Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial.

Authors:  M Hong Nguyen; Peter G Pappas; Eleftherios Mylonakis; Ioannis M Zacharioudakis; Cornelius J Clancy
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

8.  Comparison of the Performance of Three Blood Culture Systems in a Chinese Tertiary-Care Hospital.

Authors:  Guanlin Li; Jingjing Sun; Shoucheng Pan; Wenti Li; Shijie Zhang; Yongfeng Wang; Xiaoxu Sun; Hui Xu; Liang Ming
Journal:  Front Cell Infect Microbiol       Date:  2019-08-07       Impact factor: 5.293

Review 9.  Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis.

Authors:  Michael A Pfaller
Journal:  J Fungi (Basel)       Date:  2015-08-31

Review 10.  T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications.

Authors:  Ioannis M Zacharioudakis; Fainareti N Zervou; Eleftherios Mylonakis
Journal:  J Fungi (Basel)       Date:  2018-04-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.